 Alastair Robertson
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenergic beta-Antagonists | 9 | 2012 | 323 | 0.580 |
Why?
| | Propanolamines | 7 | 2012 | 96 | 0.490 |
Why?
| | Receptors, Adrenergic, alpha-2 | 3 | 2012 | 18 | 0.280 |
Why?
| | Heart Failure | 11 | 2012 | 2236 | 0.270 |
Why?
| | Receptors, Adrenergic, beta-1 | 2 | 2012 | 46 | 0.200 |
Why?
| | Heart-Assist Devices | 1 | 2008 | 552 | 0.190 |
Why?
| | Heart Transplantation | 1 | 2008 | 754 | 0.190 |
Why?
| | Enoximone | 3 | 2007 | 17 | 0.180 |
Why?
| | Cardiotonic Agents | 3 | 2007 | 124 | 0.170 |
Why?
| | Polymorphism, Genetic | 3 | 2012 | 660 | 0.160 |
Why?
| | Torsades de Pointes | 2 | 2003 | 24 | 0.100 |
Why?
| | Survival Rate | 5 | 2010 | 1972 | 0.100 |
Why?
| | Norepinephrine | 2 | 2012 | 204 | 0.100 |
Why?
| | Ventricular Fibrillation | 1 | 2012 | 60 | 0.100 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 114 | 0.100 |
Why?
| | Methadone | 2 | 2003 | 101 | 0.090 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 175 | 0.090 |
Why?
| | Clinical Trials Data Monitoring Committees | 1 | 2010 | 6 | 0.090 |
Why?
| | Hospital Records | 1 | 2010 | 12 | 0.090 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2003 | 385 | 0.080 |
Why?
| | Research Personnel | 1 | 2010 | 173 | 0.070 |
Why?
| | Middle Aged | 14 | 2012 | 33479 | 0.060 |
Why?
| | Ventricular Function, Right | 2 | 2006 | 285 | 0.060 |
Why?
| | Ventricular Function | 1 | 2006 | 61 | 0.060 |
Why?
| | Hemodynamics | 4 | 2006 | 1113 | 0.060 |
Why?
| | Myocardial Contraction | 1 | 2007 | 341 | 0.060 |
Why?
| | Metoprolol | 2 | 2002 | 40 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2005 | 106 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 89 | 0.060 |
Why?
| | Stroke Volume | 4 | 2012 | 612 | 0.060 |
Why?
| | Carbazoles | 2 | 2002 | 83 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2012 | 1477 | 0.060 |
Why?
| | Male | 18 | 2012 | 67762 | 0.050 |
Why?
| | Ventricular Function, Left | 3 | 2012 | 534 | 0.050 |
Why?
| | Nuclear Lamina | 1 | 2003 | 10 | 0.050 |
Why?
| | Hypertension, Pulmonary | 2 | 2006 | 1910 | 0.050 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2003 | 52 | 0.050 |
Why?
| | Hospitalization | 2 | 2010 | 2199 | 0.050 |
Why?
| | Female | 17 | 2012 | 73304 | 0.050 |
Why?
| | Dobutamine | 1 | 2002 | 39 | 0.050 |
Why?
| | Long QT Syndrome | 1 | 2003 | 70 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 134 | 0.050 |
Why?
| | Treatment Outcome | 7 | 2012 | 10811 | 0.050 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2003 | 121 | 0.050 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2002 | 127 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2006 | 1774 | 0.050 |
Why?
| | Retrospective Studies | 6 | 2012 | 15657 | 0.040 |
Why?
| | Gene Expression | 2 | 2006 | 1502 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2003 | 341 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2004 | 696 | 0.040 |
Why?
| | Humans | 19 | 2012 | 137585 | 0.040 |
Why?
| | Myocytes, Cardiac | 1 | 2003 | 526 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2007 | 2057 | 0.030 |
Why?
| | Myocardium | 1 | 2002 | 1002 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1509 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 1993 | 0.030 |
Why?
| | Adult | 9 | 2012 | 37929 | 0.030 |
Why?
| | Heart Ventricles | 2 | 2012 | 788 | 0.030 |
Why?
| | Aged | 7 | 2012 | 23961 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2002 | 1000 | 0.030 |
Why?
| | Administration, Oral | 2 | 2007 | 816 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2003 | 2426 | 0.030 |
Why?
| | Homozygote | 1 | 2012 | 203 | 0.020 |
Why?
| | Area Under Curve | 1 | 2012 | 314 | 0.020 |
Why?
| | Heterozygote | 1 | 2012 | 293 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 530 | 0.020 |
Why?
| | Follow-Up Studies | 3 | 2007 | 5131 | 0.020 |
Why?
| | Phenotype | 3 | 2006 | 3196 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2012 | 180 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2012 | 405 | 0.020 |
Why?
| | Aged, 80 and over | 3 | 2009 | 7635 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 889 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2003 | 1062 | 0.020 |
Why?
| | Electrocardiography | 2 | 2003 | 629 | 0.020 |
Why?
| | Genotype | 2 | 2003 | 1916 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2007 | 56 | 0.020 |
Why?
| | Pain | 2 | 2003 | 756 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2074 | 0.020 |
Why?
| | Prognosis | 2 | 2007 | 4030 | 0.020 |
Why?
| | Psychological Tests | 1 | 2007 | 140 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2007 | 171 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 413 | 0.020 |
Why?
| | Chronic Disease | 2 | 2002 | 1793 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2010 | 911 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2005 | 76 | 0.020 |
Why?
| | United States | 3 | 2010 | 14841 | 0.020 |
Why?
| | Health Surveys | 1 | 2007 | 514 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 786 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2006 | 307 | 0.010 |
Why?
| | Models, Biological | 1 | 2012 | 1783 | 0.010 |
Why?
| | Cardiomegaly | 1 | 2006 | 175 | 0.010 |
Why?
| | Severity of Illness Index | 2 | 2003 | 2828 | 0.010 |
Why?
| | RNA, Messenger | 2 | 2003 | 2833 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2005 | 310 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 767 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 976 | 0.010 |
Why?
| | Psychometrics | 1 | 2007 | 720 | 0.010 |
Why?
| | Hypokalemia | 1 | 2003 | 24 | 0.010 |
Why?
| | Radionuclide Angiography | 1 | 2002 | 5 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2003 | 52 | 0.010 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 114 | 0.010 |
Why?
| | Angiotensin II | 1 | 2003 | 99 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 2002 | 40 | 0.010 |
Why?
| | Heroin Dependence | 1 | 2002 | 33 | 0.010 |
Why?
| | Ventricular Myosins | 1 | 2002 | 35 | 0.010 |
Why?
| | Probability | 1 | 2003 | 304 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 431 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2006 | 956 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2003 | 399 | 0.010 |
Why?
| | Pedigree | 1 | 2003 | 514 | 0.010 |
Why?
| | Canada | 1 | 2002 | 418 | 0.010 |
Why?
| | Cadherins | 1 | 2003 | 206 | 0.010 |
Why?
| | Drug Interactions | 1 | 2002 | 410 | 0.010 |
Why?
| | Myosin Heavy Chains | 1 | 2002 | 192 | 0.010 |
Why?
| | Pulmonary Circulation | 1 | 2003 | 429 | 0.010 |
Why?
| | Exercise Test | 1 | 2004 | 625 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2003 | 597 | 0.010 |
Why?
| | Adolescent | 3 | 2006 | 21513 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2004 | 1266 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 7604 | 0.010 |
Why?
| | Blotting, Western | 1 | 2003 | 1226 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2002 | 1066 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2003 | 739 | 0.010 |
Why?
| | Research Design | 1 | 2005 | 1139 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2139 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1738 | 0.010 |
Why?
| | Child, Preschool | 2 | 2003 | 11074 | 0.010 |
Why?
| | Prevalence | 1 | 2003 | 2734 | 0.010 |
Why?
| | Opioid-Related Disorders | 1 | 2003 | 515 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2003 | 1991 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 5778 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3566 | 0.010 |
Why?
| | Risk Assessment | 1 | 2003 | 3457 | 0.010 |
Why?
| | Cohort Studies | 1 | 2003 | 5742 | 0.010 |
Why?
| | Time Factors | 1 | 2002 | 6828 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2003 | 6079 | 0.010 |
Why?
| | Infant | 1 | 2003 | 9465 | 0.000 |
Why?
| | Risk Factors | 1 | 2002 | 10388 | 0.000 |
Why?
| | Child | 1 | 2003 | 21935 | 0.000 |
Why?
|
|
Robertson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|